HIGHLIGHTS
- who: Li-ming Zhao from the Nanjing Medical University, China have published the article: Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma, in the Journal: (JOURNAL)
- what: At the same time, the study found that, with the continuous increase of TMB, the progression free survival (PFS) and objective response rate of CCA patients treated with ICIs may increase . The specificity and targeting of the therapy are the research focus at present and the advanced direction in the future.
- how: These data showed that nivolumab might provide a novel therapeutic choice for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.